BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Buformin

An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.

84+ PubMed studies analyzed · Evidence Score: 43

Research Domains

Buformin has been studied across 17 research domains including 🔥 Metabolic, 🧬 Hormones, 🔬 Oncology, 🫁 Liver & Detox, ❤️ Cardiovascular. The primary research focus is 🔥 Metabolic with 76% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Buformin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Loteprednol
2 shared targets
Ethylenethiourea
2 shared targets
Ascorbic
2 shared targets
Ascorbic
2 shared targets
Ethanolamine
2 shared targets
thiophanate
2 shared targets
fluoranthene
2 shared targets
Methylnitronitrosoguanidine
2 shared targets
Methandrostenolone
2 shared targets
Furazolidone
2 shared targets
Loading evidence profile...

This evidence profile for Buformin is generated deterministically from 84 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.